Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA

Condition:   Immunotherapy With Pembrolizumab for Nasopharyngeal Carcinoma Patients
Intervention:   Drug: Pembrolizumab
Sponsors:   National Health Research Institutes, Taiwan;   National Taiwan University Hospital;   Koo Foundation Sun Yat-Sen Cancer Center;   Chang Gung Memorial Hospital;   Taichung Veterans General Hospital;   China Medical University Hospital;   Changhua Christian Hospital;   National Cheng-Kung University Hospital
Not yet recruiting

https://ift.tt/2IZ4YMK